{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:31:24Z","timestamp":1793709084970,"version":"4.6.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014840","name":"G-BA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014840","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014840","name":"G-BA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014840","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014840","name":"G-BA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014840","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract\n<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>First-line therapy for patients with clinically relevant obstructive sleep apnoea (OSA) is positive airway pressure therapy (PAP). At least one half of patients with mild to moderate OSA (apnoea-hypopnoea-index (AHI) 5-30\/h) have positional OSA (POSA), where apnoea occurs mostly in supine sleep. These patients might benefit from sleep-position therapy (SPT) which should reduce sleeping time spent in a supine position. Until now, it is unclear whether SPT is non-inferior to PAP therapy for symptom relief in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a multicentre, non-inferiority, open-label randomised, cross-over clinical trial. Patients with mild to moderate POSA and daytime sleepiness (according to Epworth Sleepiness Scale (ESS) &gt; 10 points) will be randomised with a 1:1 allocation ratio, stratified by centre and AHI, to start with either PAP therapy or SPT and treated for 12 weeks. After a wash-out period of two weeks, they will switch to the other therapy for 12 weeks. The primary outcome is daytime sleepiness measured by the ESS at the end of each treatment phase. Analysis will be done in the intention-to-treat population using a linear mixed-effects model containing the intervention, the phase, the interaction between therapy and phase (including the carry-over effect) and the baseline measurement of the ESS and AHI as fixed effect, and centre and patient as random effects. A one-sided test at significant level of 2.5% will be used to test the non-inferiority of SPT with a non-inferiority margin of 1.35. Based on a sample size calculation with a one-sided one-sample t-test at significant level of 2.5%, assuming a standard deviation of 4, a total of 418 patients should be included to reach 80% power when SPT is only slightly inferior to PAP therapy (difference 0.8 resulting in a delta of 0.55 (1.35-0.8)). Assuming a 5% drop-out rate, 220 patients per sequence should be included. Possible futility stopping is planned at an interim analysis after 300 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The recruitment of patients with mild to moderate POSA is feasible with the planned centres. Both certified interventions (PAP and SPT) are covered by the statutory health insurance companies as part of the trial guideline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>DRKS00033048 registered 17. June 2024, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.drks.de\" ext-link-type=\"uri\">http:\/\/www.drks.de<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-09007-1","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T14:04:05Z","timestamp":1755525845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-inferiority of sleep position therapy compared to positive airway pressure therapy with regard to daytime sleepiness in patients with mild to moderate position-dependent obstructive sleep apnoea (POSA): study protocol for a multicentre randomised cross-over trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-4326","authenticated-orcid":false,"given":"Nina","family":"Timmesfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Valbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Spillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sch\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"6","key":"9007_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540\u20135. Available from: https:\/\/academic.oup.com\/sleep\/article\/14\/6\/540\/2742871?login=true.","journal-title":"Sleep"},{"key":"9007_CR2","doi-asserted-by":"publisher","first-page":"15015","DOI":"10.1038\/nrdp.2015.15","volume":"1","author":"P L\u00e9vy","year":"2015","unstructured":"L\u00e9vy P, Kohler M, McNicholas WT, Barb\u00e9 F, McEvoy RD, Somers VK, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015;1:15015.","journal-title":"Nat Rev Dis Primers"},{"key":"9007_CR3","unstructured":"Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertrags\u00e4rztlichen Versorgung. Available from: URL: https:\/\/www.g-ba.de\/downloads\/62-492-2901\/MVV-RL-2022-05-19-iK-2022-08-05.pdf. Cited 2022 Nov 2."},{"issue":"8","key":"9007_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S2213-2600(19)30198-5","volume":"7","author":"AV Benjafield","year":"2019","unstructured":"Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687\u201398.","journal-title":"Lancet Respir Med"},{"key":"9007_CR5","unstructured":"Deutsche Gesellschaft f\u00fcr Schlafforschung. S3-Leitlinie Nicht erholsamer Schlaf\/Schlafst\u00f6rungen \u2013 Kapitel \u201eSchlafbezogene Atmungsst\u00f6rungen\u201c: S3-Leitlinie Schlafbezogene Atmungsst\u00f6rungen. Available from: URL: https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/063-001.html. Cited 2022 Nov 2."},{"issue":"7","key":"9007_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.5664\/jcsm.7868","volume":"15","author":"RB Berry","year":"2019","unstructured":"Berry RB, Uhles ML, Abaluck BK, Winslow DH, Schweitzer PK, Gaskins RA, et al. NightBalance sleep position treatment device versus auto-adjusting positive airway pressure for treatment of positional obstructive sleep apnea. J Clin Sleep Med. 2019;15(7):947\u201356.","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"9007_CR7","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/thorax-2021-218402","volume":"78","author":"AS ALQarni","year":"2023","unstructured":"ALQarni AS, Turnbull CD, Morrell MJ, Kelly JL. Efficacy of vibrotactile positional therapy devices on patients with positional obstructive sleep apnoea: a systematic review and meta-analysis. Thorax. 2023;78(11):1126\u201334.","journal-title":"Thorax"},{"issue":"2","key":"9007_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Rese. 1989;28(2):193\u2013213. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/0165178189900474.","journal-title":"Psychiatry Rese"},{"key":"9007_CR9","unstructured":"American Academy of Sleep Medicine \u2013 Association for Sleep Clinicians and Researchers. The AASM manual for the scoring of sleep and associated events. 2024. Available from: URL: https:\/\/aasm.org\/clinical-resources\/scoring-manual\/. Cited 2024 Oct 9."},{"issue":"7","key":"9007_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/sleep\/32.7.915","volume":"32","author":"ER Chasens","year":"2009","unstructured":"Chasens ER, Ratcliffe SJ, Weaver TE. Development of the FOSQ-10: a short version of the functional outcomes of sleep questionnaire. Sleep. 2009;32(7):915\u20139. Available from: https:\/\/academic.oup.com\/sleep\/article\/32\/7\/915\/2679667?login=true.","journal-title":"Sleep"},{"key":"9007_CR11","unstructured":"EuroQol. Terminology. EuroQol; 2024. Available from: URL: https:\/\/euroqol.org\/information-and-support\/documentation\/terminology\/. Cited 2024 Oct 6."},{"issue":"4","key":"9007_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/thoraxjnl-2018-211959","volume":"74","author":"S Crook","year":"2019","unstructured":"Crook S, Sievi NA, Bloch KE, Stradling JR, Frei A, Puhan MA, et al. Minimum important difference of the Epworth Sleepiness Scale in obstructive sleep apnoea: estimation from three randomised controlled trials. Thorax. 2019;74(4):390\u20136.","journal-title":"Thorax"},{"issue":"4","key":"9007_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/thoraxjnl-2019-213547","volume":"75","author":"Y Mok","year":"2020","unstructured":"Mok Y, Tan A, Hsu PP, Seow A, Chan YH, Wong HS, et al. Comparing treatment effects of a convenient vibratory positional device to CPAP in positional OSA: a crossover randomised controlled trial. Thorax. 2020;75(4):331\u20137.","journal-title":"Thorax"},{"issue":"2","key":"9007_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5664\/jcsm.7638","volume":"15","author":"SP Patil","year":"2019","unstructured":"Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2019;15(2):301\u201334.","journal-title":"J Clin Sleep Med"},{"key":"9007_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.911996","volume":"13","author":"Z Li","year":"2022","unstructured":"Li Z, Cai S, Wang J, Chen R. Predictors of the efficacy for daytime sleepiness in patients with obstructive sleep apnea with continual positive airway pressure therapy: a meta-analysis of randomized controlled trials. Front Neurol. 2022;13: 911996.","journal-title":"Front Neurol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09007-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09007-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09007-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T05:44:44Z","timestamp":1757396684000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09007-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9007"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09007-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained on 22 May 2024. All participating patients will provide written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"NT, FV, AS, JW, AN: The authors declare that they have no competing interests.CS received institutional lecture and consulting fees from Astra-Zeneca, Berlin-Chemie, Bioprojet, Bristol-Myers Squibb, Chiesi, Eli Lilly, Idorsia, Inspire, Jazz, Mementor, Philips-Respironics, Pfizer, ResMed, ZOLL. He also received institutional research grants from Bayer, Mementor, Nox Medical, ResMed, Sleepiz as well as public funding by the German Federal Ministry for Economic Affairs and Climate Action, German Federal Ministry of Education and Research, German Federal Joint Committee, German Research Foundation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"295"}}